Drug Database
Back to search

Netherlands· NL-f6c852cbdb45

Ezmekly 2 mg harde capsules

A mirdametinib product containing mirdametinib, registered in Netherlands by Merck Europe B.V.. The same ATC class is registered in 11 of our 19 countries.

ATC L01EE05

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedEzmekly 2 mg harde capsulesATCL01EE05REGISTER NO.NL-f6c852cbdb45PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about mirdametinibAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Mirdametinib is registered in 11 of 19 countries.

Countries holding a registration under ATC L01EE05 (mirdametinib), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 9 of them publish a price we can compare per daily dose
Search mirdametinib products by name

Mirdametinib · ATC L01EE05

11 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Spainprice
  • Switzerlandprice
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
MIRDAMETINIB
Manufacturer
Merck Europe B.V.
Country
Netherlands (NL)
ATC code
L01EE05
ATC class
Mirdametinib
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/25/1950

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Mirdametinib in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All mirdametinib products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Ezmekly
  • Liechtenstein · Ezmekly
  • Norway · Ezmekly

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f0deb770-d96b-4d0e-8e83-05de4d568834
GET /v1/drugs/f0deb770-d96b-4d0e-8e83-05de4d568834?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Capsule, hard",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/ezmekly-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Mirdametinib",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp133933",
  "excipients": [
    "AMMONIA (E 527)",
    "BRILJANTBLAUW FCF (E 133)",
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "CROSCARMELLOSE  NATRIUM  (E 468)",
    "GELATINE (E 441)",
    "IJZEROXIDE GEEL (E 172)",
    "KALIUMHYDROXIDE (E 525)",
    "MAGNESIUMSTEARAAT (E 470b)",
    "PROPYLEENGLYCOL (E 1520)",
    "SCHELLAK (E 904)",
    "TITAANDIOXIDE (E 171)",
    "TITAANDIOXIDE (E 171)",
    "WITTE INKT"
  ],
  "substances": [
    "MIRDAMETINIB"
  ],
  "leaflet_url": null,
  "authorised_at": "2025/07/17",
  "procedure_number": "EMEA/H/C/006460",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/25/1950",
  "additional_monitoring": "Y"
}
API referenceMCP serverPlans

See everything about mirdametinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console